

"Express Mail" mailing label number

E 832896 930 US

Date of Deposit

9-28-04

10/509772

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DT04 Rec'd PCT/PTO 28 SEP 2004

BRYAN THOMAS

Printed Name

Bryan Thomas

Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bryan Glenn Johnson and Darryle Darwin Schoepp

For: THERAPY FOR PSYCHOSES COMBINING AN ATYPICAL  
ANTIPSYCHOTIC AND AN MGLU2/3 RECEPTOR AGONIST

Docket No.: X-15407

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



Arvie J. Anderson  
Attorney for Applicants  
Registration No. 45,263  
Phone: 317-277-7217

Eli Lilly and Company  
Patent Division/AJA  
P.O. Box 6288  
Indianapolis/Indiana 46206-6288

9/27/04

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15407	Pat. No. <b>10/509772</b>
	Applicants Bryan Glenn Johnson and Darryle Darwin Schoepp	
	Filing Date	Group

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 5,955,459 A	09/21/1999	Bradley et al.	
	AB	US			
	AC	US			
	AD	US			
	AE	US			
	AF	US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number 4-Kind Code <sup>5</sup> (if known)				
	BA					
	BB					
	BC					

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	Rowley et al: "Current and Novel Approaches to the Drug Treatment of Schizophrenia" Journal of Medicinal Chemistry, vol. 44, no. 4, 02/15/2001 pages 477-501, XP001161255	
	CB	Aghajanian and Marek: "Serotonin-Glutamate Interactions: A New Target for Antipsychotic Agents" vol. 21, no. Suppl. 6, 12/1999, ;ages S122-S133, XP001161252	
	CC	Cartmell et al: "Acute Increases in Monoamine Release in the Rat Prefrontal Cortex by the mGlu2/3 Agonist LY379268 are Similar in Profile to Risperidone, Not Locally Mediated, and Can be Elicited in the Presence of Uptake Blockade" Neuropharmacology, vol. 40, no. 7, 06/2001, pages 847-855, XP001161251	
	CD		
	CE		
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.